A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease Patients

Trial Profile

A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease Patients

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Pegunigalsidase alfa (Primary)
  • Indications Fabry's disease
  • Focus Therapeutic Use
  • Acronyms BRIGHT
  • Sponsors Protalix Biotherapeutics
  • Most Recent Events

    • 09 Aug 2017 According to a Protalix BioTherapeutics media release, this study is expected to initiate its first site this month.
    • 11 Jan 2017 Planned primary completion date changed from 1 May 2016 to 1 Jul 2018.
    • 11 Jan 2017 Status changed from withdrawn prior to enrolment to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top